Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2021 Feb 15;11(2):e040220.
doi: 10.1136/bmjopen-2020-040220.

Protocol for a quasi-experimental study to assess the feasibility, acceptability and costs of multiple first-lines artemisinin-based combination therapies for uncomplicated malaria in the Kaya health district, Burkina Faso

Mohamadou Siribie  1 , André-Marie Tchouatieu  2 , Issiaka Soulama  3 , Jean Moise Tanga Kaboré  3 , Yacouba Nombré  4 , Denise Hien  3 , Alice Kiba Koumaré  4 , Nouhoun Barry  3 , Adama Baguiya  5 , Alimatou Héma  3 , Frédéric Dianda  4 , Yacouba Savadogo  4 , Seni Kouanda  6 , Alfred Bewendtaoré Tiono  3 , Sodiomon Bienvenu Sirima  3
Affiliations

Protocol for a quasi-experimental study to assess the feasibility, acceptability and costs of multiple first-lines artemisinin-based combination therapies for uncomplicated malaria in the Kaya health district, Burkina Faso

Mohamadou Siribie et al. BMJ Open. .

Abstract

Introduction: As demonstrated in mathematical models, the simultaneous deployment of multiple first-line therapies (MFT) for uncomplicated malaria, using artemisinin-based combination therapies (ACTs), may extend the useful therapeutic life of the current ACTs. This is possible by reducing drug pressure and slowing the spread of resistance without putting patients' life at risk. We hypothesised that a simultaneous deployment of three different ACTs is feasible, acceptable and can achieve high coverage rate if potential barriers are properly identified and addressed.

Methods and analysis: We plan to conduct a quasi-experimental study in the Kaya health district in Burkina Faso. We will investigate a simultaneous deployment of three ACTs, artemether-lumefantrine, pyronaridine-artesunate, dihydroartesinin-piperaquine, targeting three segments of the population: pregnant women, children under five and individuals aged five years and above. The study will include four overlapping phases: the formative phase, the MFT deployment phase, the monitoring and evaluation phase and the post-evaluation phase. The formative phase will help generate baseline information and develop MFT deployment tools. It will be followed by the MFT deployment phase in the study area. The monitoring and evaluation phase will be conducted as the deployment of MFT progresses. Cross-sectional surveys including desk reviews as well as qualitative and quantitative research methods will be used to assess the study outcomes. Quantitatives study outcomes will be measured using univariate, bivariate and multivariate analysis, including logistic regression and interrupted time series analysis approach. Content analysis will be performed on the qualitative data.

Ethics and dissemination: The Health Research Ethics Committee in Burkina Faso approved the study (Clearance no. 2018-8-113). Study findings will be disseminated through feedback meetings with local communities, national workshops, oral presentations at congresses, seminars and publications in peer-reviewed scientific journals.

Trial registration number: NCT04265573.

Keywords: chemotherapy; epidemiology; public health; tropical medicine.

PubMed Disclaimer

Conflict of interest statement

Competing interests: None declared.

Figures

Figure 1
Figure 1
Design of the programme. MFT, multiple first-line therapies.
Figure 2
Figure 2
Artemisinin-based combination therapies flow in the framework of the multiple first-line therapies programme. ACT, artemisinin-based combination therapies; CAMEG, central essential drugs store.
See this image and copyright information in PMC

References

    1. Sécretariat Général, Ministère de la Sante, Direction Générale des Etudes et des Statistiques Sectorielles BF . Annuaire statistique 2018, 2019.
    1. Santé Mde, PNLP BF. Plan stratégique 2016-2020 de lutte contre Le paludisme Au Burkina Faso, 2015.
    1. Santé Mdela, PNLP BF. Directives nationales de prise en charge Du paludisme Au Burkina Faso, 2017.
    1. Sagara I, Beavogui AH, Zongo I, et al. . Safety and efficacy of re-treatments with pyronaridine-artesunate in African patients with malaria: a substudy of the WANECAM randomised trial. Lancet Infect Dis 2016;16:189–98. 10.1016/S1473-3099(15)00318-7 - DOI - PMC - PubMed
    1. West African Network for Clinical Trials of Antimalarial Drugs (WANECAM) Pyronaridine-artesunate or dihydroartemisinin-piperaquine versus current first-line therapies for repeated treatment of uncomplicated malaria: a randomised, multicentre, open-label, longitudinal, controlled, phase 3b/4 trial. Lancet 2018;391:1378–90. 10.1016/S0140-6736(18)30291-5 - DOI - PMC - PubMed

Publication types

Associated data